Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases

Eur J Med Chem. 2023 Jun 29;258:115613. doi: 10.1016/j.ejmech.2023.115613. Online ahead of print.ABSTRACTMany populations worldwide are suffering from central nervous system (CNS) diseases such as brain tumors, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease and Huntington's disease) and stroke. There is a shortage of effective drugs for most CNS diseases. As one of the regulatory mechanisms of epigenetics, the particular role and therapeutic benefits of histone deacetylases (HDACs) in the CNS have been extensively studied. In recent years, HDACs have attracted increasing attention as potential drug targets for CNS diseases. In this review, we summarize the recent applications of representative histone deacetylases inhibitors (HDACis) in CNS diseases and discuss the challenges in developing HDACis with different structures and better blood-brain barrier (BBB) permeability, hoping to promote the development of more effective bioactive HDACis for the treatment of CNS diseases.PMID:37399711 | DOI:10.1016/j.ejmech.2023.115613
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Source Type: research